| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/18/2010 | US20100068174 Combination with bis (thiohydrazide amides) for treating cancer |
| 03/18/2010 | US20100068171 Injectable bone/polymer composite bone void fillers |
| 03/18/2010 | US20100068170 Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| 03/18/2010 | US20100068169 Monolithic drug delivery system |
| 03/18/2010 | US20100068168 Thermal responsive polymer siloxanes, compositions, and method and applications related thereto |
| 03/18/2010 | US20100068167 Low Salt Forms of Polyallylamine |
| 03/18/2010 | US20100068166 Oral composition comprising dimethicone copolyol |
| 03/18/2010 | US20100068162 Compositions Having Silicone Properties |
| 03/18/2010 | US20100068158 Cleansing Composition |
| 03/18/2010 | US20100068156 Ampholytic copolymer based on quaternized nitrogen-containing monomers |
| 03/18/2010 | US20100068150 Selective Caspase Inhibitors |
| 03/18/2010 | US20100068141 Use of heat shock to treat ocular disease |
| 03/18/2010 | US20100068138 Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| 03/18/2010 | US20100068135 Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| 03/18/2010 | DE102008046995A1 2-Ethoxy-benzoesäurederivat 2-ethoxy-benzoic acid |
| 03/18/2010 | DE102008046987A1 Phenylmalonsäurederivate Phenylmalonsäurederivate |
| 03/18/2010 | CA2773031A1 Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| 03/18/2010 | CA2737388A1 Methods and compositions for modulating ire1, src, and abl activity |
| 03/18/2010 | CA2737218A1 Metalloporphyrin derivatives, nanoparticles comprising the same, and use thereof for photodynamic therapy |
| 03/18/2010 | CA2737163A1 Methods of treatment of hyperuricemia and associated disease states |
| 03/18/2010 | CA2737058A1 Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| 03/18/2010 | CA2736988A1 Compounds for the treatment of hepatitis c |
| 03/18/2010 | CA2736871A1 Nicotinic attenuation of cns inflammation and autoimmunity |
| 03/18/2010 | CA2736812A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion |
| 03/18/2010 | CA2736780A1 Solvent extraction microencapsulation with tunable extraction rates |
| 03/18/2010 | CA2736773A1 Noscapine and noscapine analogs and their use in treating infectious diseases by tubulin binding inhibition |
| 03/18/2010 | CA2736732A1 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| 03/18/2010 | CA2736623A1 Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
| 03/18/2010 | CA2736568A1 Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| 03/18/2010 | CA2736559A1 Novel pharmaceutical composition for treating nociceptive pain |
| 03/18/2010 | CA2736554A1 Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1h-pyrazole methanesulfonate and methods for their preparation |
| 03/18/2010 | CA2736547A1 Method for delivering a pharmaceutical composition to patient in need thereof |
| 03/18/2010 | CA2736530A1 Piperazine derivatives for binding and imaging amyloid plaques and their use |
| 03/18/2010 | CA2736522A1 Aza-benzimidazolone chymase inhibitors |
| 03/18/2010 | CA2736500A1 Local delivery of water-soluble or water-insoluble therapeutic agents to the surface body lumens |
| 03/18/2010 | CA2736381A1 Methods of using sustained release aminopyridine compositions |
| 03/18/2010 | CA2736380A1 Compositions comprising polymers having amino sugar units and methods of making and using same |
| 03/18/2010 | CA2736370A1 Pyrazole carboxamide inhibitors of factor xa |
| 03/18/2010 | CA2736362A1 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
| 03/18/2010 | CA2736295A1 Pyrrolidin-2-ones as hdm2 ligands |
| 03/18/2010 | CA2736250A1 Treatment of pervasive developmental disorders with redox-active therapeutics |
| 03/18/2010 | CA2736245A1 Methods for the administration of iloperidone |
| 03/18/2010 | CA2736130A1 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| 03/18/2010 | CA2736121A1 Method for controlling plant disease |
| 03/18/2010 | CA2736039A1 Novel prostaglandin i2 derivative |
| 03/18/2010 | CA2735417A1 Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent |
| 03/18/2010 | CA2735369A1 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 03/18/2010 | CA2735368A1 Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| 03/18/2010 | CA2735184A1 Heteroaryls amide derivatives and their use as glucokinase activators |
| 03/18/2010 | CA2734819A1 Organic compounds |
| 03/18/2010 | CA2734309A1 Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds |
| 03/18/2010 | CA2734034A1 New benzimidazole derivatives |
| 03/18/2010 | CA2732612A1 Isoquinolinone derivatives as nk3 antagonists |
| 03/18/2010 | CA2731660A1 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus |
| 03/18/2010 | CA2730561A1 Modified release ramipril compositions and uses thereof |
| 03/17/2010 | EP2163643A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 03/17/2010 | EP2163625A1 IL-17 and IL-17R homologous polypeptides and therapeutic uses thereof |
| 03/17/2010 | EP2163557A1 Function-selective vitamin d receptor agonist |
| 03/17/2010 | EP2163555A1 New pyrazole derivatives and diabetic medicine containing them |
| 03/17/2010 | EP2163554A1 Pyrimidodiazepinone derivative |
| 03/17/2010 | EP2163553A1 Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof |
| 03/17/2010 | EP2163552A1 Indole derivatives and their use as antitumor agents |
| 03/17/2010 | EP2163548A1 Prophylactic or therapeutic agent for age-related macular degeneration |
| 03/17/2010 | EP2163546A1 Quinazoline derivatives |
| 03/17/2010 | EP2163543A1 Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity |
| 03/17/2010 | EP2163541A1 Piperazine derivatives for binding and imaging amyloid plaques and their use |
| 03/17/2010 | EP2163259A1 Use of an Ang-(1-7) receptor agonist in acute lung injury |
| 03/17/2010 | EP2163258A1 Preventive/remedy for cancer |
| 03/17/2010 | EP2163252A1 Composition containing licorice-derived polyphenol |
| 03/17/2010 | EP2163249A1 Infusion solution for peripheral intravenous administration |
| 03/17/2010 | EP2163248A1 Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases |
| 03/17/2010 | EP2163247A1 USE OF NARINGENIN AND NARINGIN AS INHIBITORS FOR TRANSFORMING GROWTH FACTOR-beta1 SIGNALING PATHWAY |
| 03/17/2010 | EP2163246A1 Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
| 03/17/2010 | EP2163245A1 Renin inhibitors for the treatment of psoriasis |
| 03/17/2010 | EP2163244A1 Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence |
| 03/17/2010 | EP2163241A1 Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| 03/17/2010 | EP2163240A1 A method for the production of bioadhesive compact matrices |
| 03/17/2010 | EP2163162A1 Compositions comprising Lactobacillus plantarum strains in combination with tannin and new Lactobacillus plantarum strains |
| 03/17/2010 | EP2162493A2 Stable and compatible polymer blends |
| 03/17/2010 | EP2162491A1 Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation |
| 03/17/2010 | EP2162458A1 Protein kinase-binding nucleosides and associated methods |
| 03/17/2010 | EP2162455A2 Pyrrolopyridine compounds, process for their preparation, and their use as medicaments |
| 03/17/2010 | EP2162454A1 Imidazopyridine kinase inhibitors |
| 03/17/2010 | EP2162453A1 Crystalline form b of olmesartan medoxomil |
| 03/17/2010 | EP2162450A1 ((bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists |
| 03/17/2010 | EP2162445A1 Heterobicyclic compounds as kinase inhibitors |
| 03/17/2010 | EP2162442A1 Dual-acting benzoimidazole antihypertensive agents |
| 03/17/2010 | EP2162439A1 Tricyclic inhibitors of hydroxysteroid dehydrogenases |
| 03/17/2010 | EP2162438A2 Process for the preparation of ivabradine hydrochloride and polymorph thereof |
| 03/17/2010 | EP2162437A1 Enrofloxacin-hexahydrate |
| 03/17/2010 | EP2162434A2 Salts of perindopril |
| 03/17/2010 | EP2162427A1 Benzamides useful as s1p receptor modulators |
| 03/17/2010 | EP2162190A1 Biphenylcarboxamide derivatives as hedgehog pathway modulators |
| 03/17/2010 | EP2162158A2 Coated hyaluronic acid particles |
| 03/17/2010 | EP2162156A2 Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 03/17/2010 | EP2162141A1 Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue |
| 03/17/2010 | EP2162139A1 Curing accelerator and method of making |
| 03/17/2010 | EP2162137A1 Methods of treating cognitive disorders by inhibition of gpr12 |
| 03/17/2010 | EP2162136A1 Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| 03/17/2010 | EP2162135A1 Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |